HB1402 - Abortion-Inducing Drugs Safety Act Summary

• Requires abortion-inducing drugs to be prescribed, administered, and dispensed only by physicians following FDA-approved protocols as outlined in final printed labeling, with specific prohibitions on off-label use variations.

• Mandates physicians examine pregnant women in person, verify intrauterine pregnancy location, determine blood type, offer RhoGAM if Rh negative, and document gestational age in medical records before providing abortion-inducing drugs.

• Prohibits distribution of abortion-inducing drugs via courier, delivery, or mail service and requires physicians to have signed agreements with associated physicians credentialed to handle abortion complications.

• Requires physicians to schedule follow-up visits 7-14 days after drug administration to confirm complete pregnancy termination and assess bleeding, with documented efforts to ensure patient attendance.

• Includes detailed legislative findings regarding FDA approval restrictions, medical risks, adverse event data, and court testimony about off-label use of mifepristone and misoprostol combinations.